August 3, 2026

Between January 2025 and June 2026, five of the world's largest pharmaceutical companies changed CEOs. The appointments do not describe one archetype — they show boards selecting for the next condition rather than reproducing the last leader. For every executive one tier down, the question shifts from "am I excellent at my function?" to "have I developed the range to lead the next version of the enterprise?"








